Indeed, a number of HDAC inhibitors are therapeutically effective on a variety of hematological and solid tumors both in vitro and in vivo, including leukemia, lymphoma, lung cancer, breast cancer, melanoma, glioblastoma, uterine cervix cancer, among others [7], [10], [18], [19], [35], [36]. Here, HDAC9 is linked to melanoma.